The sale is a routine post-exercise disposition by an officer. The insider has a pattern of periodic sales, including a larger 30,000-share sale in August 2026. No unusual urgency or change in insider sentiment is indicated. Monitor upcoming quarterly filings for any change in insider selling patterns.
Price Chart
Executive Summary
Sarah Gheuens, an officer of Agios Pharmaceuticals, filed a Form 144 notice of intent to sell 7,866 shares of common stock, valued at approximately $296,468, with the proposed sale date of October 26, 2026. The shares were acquired via a stock option exercise on the same day. This is a routine insider sale following option exercise, and the amount is modest relative to the company's $2.2B market cap.
Key Facts
- Insider: Sarah Gheuens, Officer of Agios Pharmaceuticals
- Proposed sale of 7,866 shares of common stock
- Approximate value: $296,467.97
- Proposed sale date: October 26, 2026
- Shares acquired via stock option exercise on October 26, 2026
- Prior sales by same insider: 500 shares on 10/22/2026, 1,489 shares on 10/21/2026, 30,000 shares on 08/04/2026
- Company market cap: $2.2B
Financial Impact
Sale of 7,866 shares worth ~$296K, representing less than 0.02% of market cap
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur
- Insider has sold shares multiple times in recent months, which could indicate ongoing diversification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010399 |
| Document: 0001950047-26-010399-index.html | 0001950047-26-010399 |
| Document: 0001950047-26-010399.txt | 0001950047-26-010399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 144 | $36.85 | awaiting T+60 | awaiting T+60 | $38.03 (+3.20%) |
Oct 22, 2026 5d ago | 144 | $37.00 | awaiting T+60 | awaiting T+60 | $38.03 (+2.78%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | awaiting T+60 | $38.03 (+19.03%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.03 (+16.12%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.03 (+16.12%) |
Jul 7, 2026 16w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $38.03 (−13.59%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $38.03 (−0.03%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $38.03 (+8.35%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $38.03 (+19.52%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $38.03 (+35.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers